Endurance RP Limited

壽康集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 575)

OPERATIONAL UPDATE

This announcement is made on a voluntary basis by the board (the "**Board**") of directors (the "**Directors**") of Endurance RP Limited (the "**Company**" and collectively with its subsidiaries, the "**Group**") to inform the shareholders of the Company and potential investors of the following update in respect of its operations.

Manufacturing and Resumption of Commercial Supply for Fortacin™

Our European commercial partner received approval from the European Medicines Agency on 15 September 2022 for adding an alternative European manufacturer to the dossier. Following this approval, our European commercial partner has received its first two commercial batches of Fortacin™ in February 2023 for sale in Germany and Italy. We expect sales will also continue in its other key European markets as supply is resumed over the course of 2023. Our European commercial partner has also submitted the same Fortacin™ dossier to the Medicines and Healthcare products Regulatory Agency ("**MHRA**") in the United Kingdom for the European manufacturer to be approved as a third-party manufacturer. Our European commercial partner expects to receive approval from MHRA by the end of Q1 2023. And once MHRA has approved the alternative manufacturer, Plethora Solutions Limited, a wholly-owned subsidiary of the Company, ("**Plethora**") will submit the same dossier for Senstend™ (the marketing name for Fortacin™ in The People's Republic of China ("**PRC**" or "**China**")) to MHRA so that Wanbang Biopharmaceutical Co., Ltd., the Company's commercial strategic partner for China ("**Wanbang Biopharmaceutical**") can add the alternative manufacturer to its dossier for submitting the New Drug Application ("**NDA**") in China.

We are hopeful that this new manufacturer will be able to offer continuous supply of Fortacin™ to our commercial strategic partners bringing in royalty revenue for the Group.

Chinese Approval and Commercialisation Progress

Wanbang Biopharmaceutical has confirmed that it has completed the randomisation of 295 subjects (10 more subjects than initially targeted) into the Phase 3 study, with the last subject having completed treatment at the end of January 2023. The Clinical Research Organisation is now collecting all the data and will lock the data base, with the initial data being made available in early Q2 2023. Based on Wanbang Biopharmaceutical's timeline, it remains on target to submit the NDA during Q3 2023 with approval expected 12 months later (depending on the response received from the National Medical Products Administration ("**NMPA**") with respect to any deficiencies in the submission).

A brief summary of the key points of the study are:

Registration of study:	December 2021
Study type:	Phase 3 clinical trial, multi-centre, randomised, double-blinded placebo controlled study
Estimated enrolment:	295 subjects (treatment completed)
Primary endpoint:	To determine the effects of Senstend™ on the Index of Premature Ejaculation and the Intra-vaginal Ejaculation Latency Time
Secondary endpoint:	To evaluate the safety and tolerability of Senstend™ in Premature Ejaculation subjects and their sexual partners
NDA submission:	Q3 2023

All costs of the clinical trials, including all other associated regulatory and submission costs are being met by Wanbang Biopharmaceutical. If the clinical study meets its endpoints and the NMPA grants an import licence for Senstend™, US$5 million (or approximately HK$39 million) (before deduction of PRC withholding tax) will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US$2 million (or approximately HK$15.60 million) (before deduction of PRC withholding tax) shall be payable to the Group from Wanbang Biopharmaceutical. To this end, the Company remains pleased with the progress to date and looks forward to working together with Wanbang Biopharmaceutical and its regulatory consultant on submission of and, ultimately, achieving approval of the NDA by NMPA.

United States Approval and Commercialisation Progress

By way of background, we set out below key data points of the United States (the "**US**") regulatory pathway for submission of the NDA:

On 22 December 2021, the Company submitted the Phase 2 study results entitled: "A Pilot, Randomized, Double-Blind Study Comparing the Proportion of Responders to PSD502 and Placebo Using the Premature Ejaculation Bothersome Evaluation Questionnaire (the "**PEBEQ**™") in Subjects with Premature Ejaculation" to The Food and Drug Administration of the United States (the "**FDA**").

On 13 April 2022, the FDA provided Plethora with advice/information request regarding the Final Qualitative Exit Interview Report entitled "Qualitative Exit Interviews in a Randomized, Double-Blind Multicentre Study Comparing the Proportion of Responders to PSD502 and to Placebo Using the PEBEQ™ in Subjects with Premature Ejaculation" and Psychometric Evaluation of the PEBEQ™ – ITEM 3 (event – specific bother).

On 2 June 2022, Plethora submitted a fulsome response to the FDA's information request.

On 21 September 2022, Plethora and the FDA participated in a teleconference. Plethora requested the FDA's feedback regarding their proposed Phase 3 registration study for Fortacin™.

On 20 December 2022, Plethora submitted a "Type C" meeting request to gain feedback on its exit interview protocol and interview guide.

On 22 February 2023, FDA provided Plethora with written responses to its "Type C" meeting request regarding its exit interview protocol and interview guide, which was received 5 days ahead of schedule.

Plethora is working with its regulatory consultants to incorporate all the FDA's recommendations/suggestions to submit its reply by the end of March 2023.

Plethora, at the time of submitting its updated exit interview protocol and interview guide, will request a Special Protocol Assessment ("**SPA**"), which is the pathway discussed and agreed forward with the FDA at its teleconference meeting of 21 September 2022. By way of background information, an SPA is a process in which Sponsors (e.g. Plethora) may ask to meet with the FDA to reach agreement on the design and size of its Phase 3 study. An SPA agreement indicates concurrence by FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, and planned analyses) for a study intended to support a future marketing application. These elements are critical to ensuring that the trial conducted under the protocol can be considered an adequate and well-controlled study that can support marketing approval. Feedback on these issues provides the greatest benefit to sponsors in planning late-phase development strategy. However, an SPA agreement does not indicate FDA concurrence on every protocol detail. The existence of an SPA agreement does not guarantee that FDA will file (accept) a NDA, or that the trial results will be adequate to support approval. Those issues are addressed during the review of a submitted application and are determined based on the adequacy of the overall submission.

For more information shareholders and potential investors can visit the link https://www.fda.gov/media/97618/download to understand the SPA process.

Plethora now has a roadmap for submission of the NDA that was agreed with the FDA on the teleconference of 21 September 2022 on the items required to submit the NDA. The next steps of that roadmap are submission of the revised exit interview protocol and guide followed by a request for SPA on the design and size of the Phase 3 studies.

Once the SPA and exit interview protocol have been agreed with the FDA, Plethora will request an end-of-phase 2 (EOP2) meeting ahead of starting the Phase 3 studies. We estimate that these studies will commence in the latter half of 2023, but this is dependent on the completion of the steps mentioned above.

Overall, we view our dialogue with the FDA and the agreed roadmap for submission of the NDA as a major positive development in the Company's path for the commercialisation of Fortacin™ in the US. In particular, the signing of the SPA with the FDA should allow the Company to advance negotiations to a final conclusion in respect of "out licencing" the US rights to Fortacin™ to a US strategic pharmaceutical partner.

Other Territories

Now that commercial supply has been resumed, our other commercial partners can at their liberty negotiate manufacturing and supply agreements with the alternative European manufacturer, which we expect will take place shortly.

The Group is in discussions with a Japanese pharmaceutical company for "out licencing" the rights to Fortacin™ in Japan.

The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

Deep Longevity

Deep Longevity, Inc, a wholly-owned subsidiary of the Company, ("**DLI**") is continuing its growth journey with multiple initiatives around building out the team, product, technology and commercial models. DLI is committed to building and commercialising various aging clocks using its AI led deep learning models.

The past year has been one of intense build and development for DLI. In-line with its previously outlined strategy of focusing on business-to-business (B2B) operation, it has built and commercialised SenoClock, the longevity industry's first SaaS@ platform for aging clocks. SenoClock has been launched with DLI's Blood Age clock and our first customers have been signed up. DLI's efforts will continue as it brings additional aging clocks into the SaaS@ platform, including is MindAge@ clock that will be made available in Q1 2023.

The SenoClock platform provides us with an opportunity to rapidly demo our technology and drive adoption within providers but also beyond to insurers and employers who might end up using our technology through application programming interfaces (APIs) or other methods. For more information, shareholders and investors can visit the following links:

Landing Page: https://www.deeplongevity.com/senoclock

Launch video & demo: https://www.youtube.com/watch?v=e6EXlgY7Lj0

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US$ have been translated, for the purpose of illustration only, into HK$ using the exchange rate of US$1.00 = HK$7.80.

By Order of the Board
Endurance RP Limited
Jamie Gibson
Executive Director

Hong Kong, 6 March 2023

As at the date of this announcement, the Board comprises six Directors**:**

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliff

Independent Non-Executive Directors:
David Comba
Julie Oates
Mark Searle

* For identification purposes only